Hospital
Providence Health & Services Oregon
Providence Health & Services Oregon was paid $8.78M by Medicaid between Jan 2018 and Nov 2024, across 93 billing codes. Its largest line is 99283, emergency room visit (moderate) — 47% of everything it billed.
33Billing provider infoPROVIDENCE HEALTH & SERVICES OREGON
HOOD RIVER, OR 97031
HOOD RIVER, OR 97031
33aNPI1255429338assigned 10/11/2006
33bProvider typeCritical Access Hospital
28Total paid$8.78M
24GClaims67,056
24DCodes billed93
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in Oregon
Rank by total paid#9 of 22
Median peer was paid$3.52M
This provider vs. median2.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 19,390 | $1.79M | |
| 2019 | 8,119 | $868K | |
| 2020 | 5,196 | $502K | |
| 2021 | 7,675 | $856K | |
| 2022 | 10,464 | $1.46M | |
| 2023 | 8,889 | $1.65M | |
| 2024incomplete | 7,323 | $1.65M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 47% | 17,112 | 11,313 | $4.14M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 33% | 9,665 | 6,607 | $2.85M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.0% | 2,468 | 1,597 | $704K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.0% | 1,655 | 1,168 | $89K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 103 | 100 | $82K |
| 80053 | Comprehensive metabolic panel | <1% | 5,996 | 5,104 | $75K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 379 | 313 | $71K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,710 | 6,484 | $65K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | <1% | 2,493 | 1,416 | $52K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 883 | 809 | $49K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 688 | 568 | $45K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 321 | 271 | $42K |
81 more codes
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,508 | $38K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 15 | $36K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 152 | $35K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 517 | $31K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 129 | $24K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 204 | $24K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 381 | $21K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,307 | $17K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 610 | $15K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 541 | $15K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 349 | $12K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 97 | $12K |
| 81001 | <1% | 2,072 | $11K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 90 | $11K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 67 | $11K |
| 59025 | Fetal non-stress test | <1% | 48 | $11K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 46 | $11K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 15 | $9K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 955 | $9K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 36 | $9K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 361 | $8K |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,381 | $7K |
| 80061 | Lipid panel | <1% | 233 | $7K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 210 | $6K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 444 | $6K |
| 84484 | <1% | 94 | $6K | |
| 85027 | <1% | 697 | $6K | |
| 83690 | <1% | 275 | $5K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 221 | $5K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 232 | $5K |
| J2704 | Injection, propofol, 10 mg | <1% | 249 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 240 | $4K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 85 | $4K |
| 81025 | <1% | 425 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 103 | $4K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 12 | $4K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 103 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 209 | $3K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 60 | $3K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 16 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 182 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 74 | $3K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 385 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 47 | $2K |
| 76830 | Ultrasound, transvaginal | <1% | 19 | $2K |
| 85610 | <1% | 203 | $2K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 18 | $2K |
| 84439 | <1% | 66 | $2K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 13 | $2K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 108 | $2K |
| 86803 | <1% | 73 | $2K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 97 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 479 | $1K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 36 | $1K |
| 87081 | <1% | 66 | $1K | |
| 83516 | <1% | 84 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 13 | $874.69 |
| 73610 | <1% | 13 | $868.24 | |
| 87070 | <1% | 43 | $769.45 | |
| 80305 | <1% | 86 | $760.67 | |
| 92567 | <1% | 14 | $750.20 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 32 | $749.36 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 31 | $748.82 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 28 | $712.12 |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 80 | $698.89 |
| 86850 | <1% | 60 | $671.25 | |
| 88142 | <1% | 29 | $665.97 | |
| 86900 | <1% | 82 | $635.32 | |
| 81003 | <1% | 71 | $604.11 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 16 | $573.83 |
| 87340 | <1% | 36 | $497.90 | |
| 96376 | <1% | 18 | $438.34 | |
| 86901 | <1% | 82 | $437.62 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 12 | $257.92 |
| 87510 | <1% | 15 | $250.54 | |
| 87660 | <1% | 15 | $219.62 | |
| 87480 | <1% | 15 | $214.22 | |
| 87186 | <1% | 13 | $212.06 | |
| 85652 | <1% | 12 | $207.27 | |
| 82950 | <1% | 13 | $202.58 | |
| 82247 | <1% | 15 | $38.56 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY ENROLLMENTS)
Parent organizationPROVIDENCE HEALTH & SERVICES OREGON
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.